PolyPid (PYPD) director Joseph BenAmram reports initial stock option grants

Rhea-AI Filing Summary

PolyPid Ltd. director Joseph BenAmram has reported his initial derivative holdings in company stock options. The Form 3 shows three stock option grants over ordinary shares with different exercise prices and vesting schedules. One grant covers 625 underlying shares at an exercise price of $11.4000 per share, expiring on May 8, 2033, and vests quarterly until May 8, 2026. A second grant covers 6,500 underlying shares at an exercise price of $4.2400, expiring on July 2, 2034, which was fully vested as of July 2, 2025. The third grant covers 14,440 underlying shares at an exercise price of $2.6700, expiring on June 25, 2035, and vests on a quarterly basis beginning May 12, 2025 until May 12, 2029. The filing lists these as direct holdings and does not show any new purchases or sales, only existing option positions.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider BenAmram Joseph

Role Director

Type	Security	Shares	Price	Value
holding	Stock option (right to buy)	--	--	--
holding	Stock option (right to buy)	--	--	--
holding	Stock option (right to buy)	--	--	--

Holdings After Transaction: Stock option (right to buy) — 625 shares (Direct)

Footnotes (1)

1. The options were granted on May 8, 2023 and vest on a quarterly basis until May 8, 2026. The options were granted on July 2, 2024 and fully vested as of July 2, 2025. The options were granted on June 25, 2025 and vest on a quarterly basis beginning May 12, 2025 until May 12, 2029.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

BenAmram Joseph

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET ISRAEL

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	08/08/2023	05/08/2033	Ordinary Shares	625(1)	$11.4	D
Stock option (right to buy)	10/02/2024	07/02/2034	Ordinary Shares	6,500(2)	$4.24	D
Stock option (right to buy)	08/12/2025	06/25/2035	Ordinary Shares	14,440(3)	$2.67	D

Explanation of Responses:

1. The options were granted on May 8, 2023 and vest on a quarterly basis until May 8, 2026.

2. The options were granted on July 2, 2024 and fully vested as of July 2, 2025.

3. The options were granted on June 25, 2025 and vest on a quarterly basis beginning May 12, 2025 until May 12, 2029.

	/s/ Joseph BenAmram	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does PolyPid (PYPD) director Joseph BenAmram report in this Form 3?

He reports his existing stock option holdings in PolyPid. The filing lists three option grants over ordinary shares with specific exercise prices, expiration dates, and vesting schedules, but no new purchases, sales, or exercises of shares.

How many PolyPid (PYPD) shares are covered by Joseph BenAmram’s options?

His options cover 625, 6,500, and 14,440 underlying ordinary shares in three separate grants. These positions reflect derivative rights to acquire shares at fixed exercise prices, rather than current ownership of the underlying stock itself.

What are the exercise prices of Joseph BenAmram’s PolyPid (PYPD) stock options?

The options have exercise prices of $11.4000, $4.2400, and $2.6700 per share. Each grant has its own expiration date and vesting pattern, as described in the derivative holdings and related footnotes.

When do Joseph BenAmram’s PolyPid (PYPD) options vest and expire?

One grant vests quarterly until May 8, 2026 and expires May 8, 2033. A second was fully vested as of July 2, 2025 and expires July 2, 2034. The third vests quarterly from May 12, 2025 until May 12, 2029 and expires June 25, 2035.

Does this PolyPid (PYPD) Form 3 show insider buying or selling by Joseph BenAmram?

No, it does not show insider buying or selling. The Form 3 simply discloses existing stock option positions as BenAmram becomes a reporting insider, with no reported transactions that increase or decrease his holdings.